미국 급성 호흡곤란증후군(ARDS) 시장 – 2029년까지의 산업 동향 및 예측

미국 급성 호흡곤란증후군(ARDS) 시장 분석 및 통찰력

미국 급성 호흡곤란증후군(ARDS) 시장은 2022년에서 2029년의 예측 기간 동안 상당히 성장할 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 10.6%의 CAGR로 성장하고 있으며 2029년까지 7,083.46백만 달러에 도달할 것으로 예상된다고 분석했습니다. 시장 성장을 견인하는 주요 요인은 급성 폐 손상의 유병률과 발생률 증가, ARDS에 대한 광범위한 위험 요소 및 ARDS가 있는 covid-19 환자 풀의 가속화, 대기 오염 및 생활 방식 관련 질병의 증가율, ARDS를 유발하는 사고율 및 외상 증가입니다.

급성 호흡곤란증후군(ARDS)은 폐로 체액이 새어 들어가는 생명을 위협하는 폐 손상입니다. ARDS에 걸린 대부분의 사람들은 이미 외상 이나 COVID-19와 같은 질병으로 입원했습니다. 이 증후군은 일반적으로 폐의 작고 탄력 있는 기낭인 폐포에 체액이 축적될 때 발생합니다. 이러한 체액 축적으로 인해 혈류로 도달하는 산소가 줄어듭니다. 이로 인해 장기가 정상적인 기능을 수행하는 데 필요한 산소를 충분히 얻지 못하게 됩니다. 다른 질병이 있는 사람들은 촉발된 부상이나 감염 후 몇 시간에서 며칠 이내에 ARDS를 발병합니다. 사망 위험은 나이가 들면서 증가하고 질병의 심각도에 따라 증후군에서 살아남은 환자는 힘들어집니다. 폐의 막낭에 손상을 입히는 심각한 질병이나 부상은 ARDS로 이어집니다. 해당 질병의 가장 흔한 근본 원인에는 패혈증, 유해 물질 흡입, 중증 폐렴, 머리, 가슴 또는 다른 심각한 부상, 코로나바이러스감염증 2019(COVID-19) 등이 있습니다.

미국 급성 호흡곤란증후군(ARDS) 시장 보고서는 시장 점유율, 새로운 개발, 국내 및 지역 시장 참여자의 영향에 대한 세부 정보를 제공하고, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서 기회를 분석합니다. 분석과 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.

시장 정의

급성 폐 손상의 유병률과 발생률이 증가하는 것은 미국 급성 호흡 곤란 증후군(ARDS) 시장의 중요한 원동력입니다. ARDS에 대한 광범위한 위험 요소와 ARDS가 있는 covid-19 환자 풀의 가속화는 시장 성장을 가속화합니다. 주요 제약은 미국 급성 호흡 곤란 증후군(ARDS) 시장에 부정적인 영향을 미칠 수 있습니다. 치료와 관련된 합병증 및 장치 및 치료의 높은 비용. 증가하는 노령 인구는 시장 기회를 제공할 것으로 예상됩니다. 그러나 엄격한 규칙과 규정은 미국 급성 호흡 곤란 증후군(ARDS) 시장 성장에 도전할 것으로 예상됩니다.

미국 급성 호흡곤란증후군(ARDS) 시장 동향

운전자

• 급성 폐손상의 유병률 및 발생률 증가

급성 폐 손상 환자는 노령 인구 증가, 패혈증 및 폐렴 환자 증가 등 여러 요인으로 인해 널리 보고되고 있습니다. 그러나 대부분의 사람들은 폐 손상 및 급성 호흡 곤란 증후군 진단을 후기 단계에만 받습니다. 따라서 ARDS의 발생률과 유병률은 계속 증가하고 있으며, 이 질병은 전 세계적으로 높은 이환율과 사망률 부담을 지닌 주요 임상 문제로 널리 인식되고 있습니다. 따라서 급성 폐 손상 및 수반되는 급성 호흡 곤란 증후군의 유병률과 발생률이 증가함에 따라 미국 급성 호흡 곤란 증후군(ARDS) 시장이 주도되고 있습니다.

• ARDS의 광범위한 위험 요소

An enormous range of risk factors is reported for acute respiratory distress syndrome. There are environmental and individual risk factors involved with the syndrome. Some chronic alcohol consumption and active or passive cigarette smoking have been commonly associated. Hence, increasing alcohol consumption irrespective of age leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.

• Acceleration in patient pool of covid-19 with Acute Respiratory Distress Syndrome (ARDS)

As the world is suffering enormously from COVID-19 infection, there is also a direct correlation between COVID-19 and acute respiratory distress syndrome. Severe cases of COVID-19 disease will ultimately lead to ARDS and pneumonia. This has been proven to be fatal for infected individuals. When the COVID-19-causing virus enters the body, it attaches to the upper airway cells. This sets off an immune response that causes inflammation and leads to symptoms such as cough, sore throat, and fever. In some severe cases, the virus travels beyond the upper airway, moves through the lungs, and ends up in the alveoli. Thereby, the rising number of COVID-19 cases also increases the chance of acute respiratory distress syndrome among people, which is expected to act as a driver for the growth of the acute respiratory distress syndrome market.

• The rising rate of air pollution and lifestyle-related diseases

Long-term exposure to low to moderate air pollution is associated with a greater risk factor for developing any lung infection, including ARDS. This is a novel and potentially modifiable environmental risk factor for acute respiratory distress syndrome. According to the World Health Organization, air pollution is one of the greatest environmental risks to health by increasing the burden of diseases like heart diseases and lung and respiratory infections at both acute and chronic levels. Hence, the rising air pollution rate in developed and developing countries increases the chances of people getting syndromes like acute respiratory distress syndrome. Thus, the factor is expected to drive the growth of the market.

• Increasing accident rates and trauma causing Acute Respiratory Distress Syndrome (ARDS)

Major trauma caused by accidents is a well-known risk factor for the development of ARDS. Acute respiratory distress syndrome can result from an injury to the body by creating inflammation of the pancreas, breathing contents of the stomach into the lung, blood transfusions, house fire and smoke inhalation, serious infection, drowning trauma, and severe reaction to medications. Even car accidents are a cause of ARDS. Hence, inhalation of smoke releases certain materials like fibrin, neutrophils, mucus, and epithelial cell debris that occlude the airway lumen, causing changes in ventilation. This condition leads to hypoxemia which is a primary significant reason for ARDS.

Opportunities

• Growing geriatric population

The 'world's geriatric population is increasing at a rapid rate. Older people have become an increasingly prevalent population of intensive care admissions. As per an article on National Center for Biotechnology Information (NCBI), the mortality rate associated with acute respiratory distress syndrome (ARDS) has been 69% to 80% reported among the elderly population, making it riskier for geriatric people. Thus, the growing pace of the older population demonstrates the escalation in demand for acute respiratory distress syndrome treatments as they are more vulnerable to severe respiratory illness due to their weak immune system. It is anticipated that the -increasing geriatric population, which is expected to rise in future years worldwide, creates an opportunity for market growth in the forecast period.

• Rising healthcare expenditure

Healthcare expenditure has increased worldwide as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for acute respiratory distress syndrome, as the disorder has been highly prevalent in recent years. Growing healthcare expenditure is also beneficial for further economic and healthcare sector growth. It is primarily fruitful as it significantly affects the development of better and advanced therapeutic options with ventilators and other ARDS treatment devices.

• Strategic initiatives by market players

With increasing rates of infectious diseases such as COVID-19 and chronic diseases like lung cancer, the simultaneous burden of 'syndrome like ARDS is widely seen globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives these players take. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market. These strategic product launches, acquisitions, and mergers done by major companies in the acute respiratory distress syndrome market have opened up opportunities for companies in various regions. This strategy is allowing the companies to strengthen their footprints in the market.

• Improving awareness regarding Acute Respiratory Distress Syndrome (ARDS)

Since acute respiratory distress syndrome has multiple different causes, it is usually ignored under common causes of death. The requirement of advanced technical treatment and proper awareness of the condition can substantially decline ARDS incidence. As timely diagnosis and prevention are crucial to preventing or recovering faster, the public's attention is most important. Current government and organizations have broadened the scope of lung injury research to include primary prevention of ARDS and reduce the morbidity or mortality rate for the syndrome. Thereby, increasing awareness regarding ARDS by diverse 'association's support enhances the U.S. acute respiratory distress syndrome 'market's opportunity for wide growth in the future.

Restraints/Challenges

• Complications associated with treatments

Acute respiratory distress syndrome is a clinical condition requiring proper and timely treatment and cares to prevent mortality and morbidity rates. However, during the treatment of ARDS, the patients might face many complications in the hospitals. Though there are treatments for ARDS helping people survive, the complications associated during treatments and post-treatment are still a burden for patients. Most potential and lasting effects include breathing problems, depression, problems with memory and thinking, tiredness and muscle weakness, and more. These complications associated with and post-treatment of acute respiratory distress syndrome are expected to hamper the market growth during our forecast period.

• High cost of device and treatments

Though acute respiratory distress syndrome is getting a wide range of advanced treatment options, the cost of treatment for longer is quite difficult for average-income people to afford. The utilization of critical care and intensive care unit services is increasing worldwide, and its expensive cost is a major concern in the current healthcare system. Patients with ARDS are commonly required to have long hospitalizations with frequent monetarization and ventilation usage, consuming a significant amount of healthcare resources. Therefore, the high cost of treatment and ventilators is very challenging for people to afford any reliable remedy for the long term until the patient completely recovers. This is anticipated to hamper the growth of the market.

• Lack of skilled workforce

The sudden COVID-19 crisis has created various challenges to be faced by a healthcare organization, including a workforce shortage. The pandemic massively struck developed countries like the U.S. They initiated multiple ways to overcome such challenges, but news articles reported that the countries were dealing with staffing shortages. There were shortages of nurses even before the pandemic began in the U.S., as the region has a high population with respiratory disorders. Therefore, the lack of appropriately skilled and trained nurses in the ICU will be a more remarkable restraint expected to hamper the growth of the acute respiratory distress syndrome (ARDS) market.

• Stringent rules & regulations

The use of ventilators across the globe is rapidly increasing, with the growth of the aged population and several acute lung diseases, including acute respiratory distress syndrome, which is preventable by early diagnosis and timely treatments. At the same time, the players of the acute respiratory distress syndrome manufacturers in the market have to follow specific regulations to get approval from the upper authorities to launch the product like mechanical ventilators or humidifiers. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. For example, the U.S. Food and Drug Administration (FDA) regulates respiratory ailment products in the U.S. Therefore, the stringent rules & regulations for product approval challenge the market's growth.

• Multiple challenges faced by ICU nurses

The intensive care units have many challenges to face during the pandemic due to a large patient pool and fewer hospital resources. Since the first wave of COVID-19, the hospitals have increased the capacity and potential of 'ICUs, which has led to increased working hours for ICU health care providers. The nurses dealing in ICU are always in fear due to multiple reasons for handling infected patients. Therefore, the most significant challenge is the difficulties faced by nurses and other healthcare providers dealing with acute respiratory distress syndrome and severe acute respiratory syndrome. Organizations are trying to overcome them with new innovative ideas and appointing more workforces.

Recent Development

• In July 2020, Gilead Sciences, Inc. initiated clinical testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19. This testing helped the company enhance its antiviral product portfolio, thereby strengthening its footprint on the market

U.S. Acute Respiratory Distress Syndrome (ARDS) Market Scope

U.S. acute respiratory distress syndrome (ARDS) market is categorized based on cause, type, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Cause

• Coronavirus Disease 2019 (COVID-19)
• Sepsis
• Inhalation Of Harmful Substances
• Severe Pneumonia
• Others

Based on the cause, the U.S. acute respiratory distress syndrome (ARDS) market is classified into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others.

Type

• Diagnosis
• Treatment

Based on type, the U.S. acute respiratory distress syndrome (ARDS) market is classified into diagnosis and treatment.

Route of Administration

• Oral
• Parenteral
• Others

Based on route of administration, the U.S. acute respiratory distress syndrome (ARDS) market is classified into oral, parenteral, and others.

End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Based on end-user, the U.S. acute respiratory distress syndrome (ARDS) market is classified into hospitals, specialty clinics, home healthcare, and others.

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Based on distribution channel, the U.S. acute respiratory distress syndrome (ARDS) market is classified into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others.

Competitive Landscape and U.S. Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis

미국 급성 호흡곤란증후군(ARDS) 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 미국 급성 호흡곤란증후군(ARDS) 시장과 관련된 회사의 초점에만 관련이 있습니다.

미국 급성 호흡곤란증후군(ARDS) 시장에서 활동하는 대표적인 기업으로는 Gilead Sciences, Inc., Terumo Medical Corporation, Getinge AB., Medtronic, LivaNova PLC, Fresenius SE & Co. KGaA, Drägerwerk AG & Co. KGaA, F. Hoffmann-La Roche Ltd, Fisher & Paykel Healthcare Limited., Hamilton Medical, NIPRO, Pfizer Inc., ResMed, Smiths Medical, WEINMANN Emergency Medical Technology GmbH + Co. KG 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 미국 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.

SKU-67938